The global antacids market will reach $10.50B in 2027, at a CAGR of 3.78%, according to a study by Reportlinker. Poor lifestyle adoptions such as deskbound jobs, poor sleep quality, and irregular dietary habits, which increases the acidity level of the stomach and lead to gastroesophageal reflux disease, are essential drivers for the evolution of the antacids market.
As per the American College of Gastroenterology, about 60 million Americans suffer from gastroesophageal reflux disease.
Globally, antacids are widely used for treating ulcers, inflammation, dyspepsia discomfort, sore stomach, stomach acid indigestion, and stomach upset. It is an over-the-counter (OTC) medication that neutralizes the acid in the stomach to relieve indigestion and heartburn. Further, they contain ingredients like magnesium hydroxide, sodium bicarbonate, calcium, and aluminum are commonly available in convenient chewable powder, tablets, and liquid forms. They are self-prescribed medications and act by neutralizing the acid in the stomach and inhibiting pepsin.
The development in the antacids market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had prior led to restrictive containment measures involving remote working, social distancing, and the closure of commercial activities that resulted in operational challenges.